Hematopoietic Stem Cell Transplant

Hematopoietic stem cells in the blood that may have many other applications to treat more than just cancers of the blood. Our team uses hematopoietic stem cell transplant clinical trials to find faster and more personalized tactics solutions for multiple different kinds of cancers throughout the body.

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Protocol ID: 10-CBA Diseases: Umbilical Cord Blood Transplant Who Can Participate?: There are no age restrictions. Lead Researcher: Jeffery Auletta

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients

Protocol ID: NCBP CBUs Disease: Allogeneic HSCT Who Can Participate?: Ages 0 to 99 Lead Researcher: Hemalatha Geetharani Rangarajan, MD

A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection with Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients

Protocol ID: NYMC 581-EBV Disease: Cellular Therapy Who can participate?: Patients with Epstein-Barr virus infections post allogeneic HSCT or with primaryIncreasing EBV RT-PCR DNA (by 1 log) after 7 days or persistent quantitative EBV RT-PCR DNA copies after 14 days despite two weeks of appropriate anti-viral therapy and/or progressive clinical symptoms attributable to EBV, including biopsy proven colitis, lymphadenopathy, hepatomegaly, splenomegaly and/or Medical intolerance to anti-viral therapies. Lead Researcher: Rolla F. Abu-Arja

Access Protocol for Treatment Use of the CliniMACS® CD34 Reagent System Humanitarian Use Device (HUD) for Prevention of Graft vs Host Disease (GvHD) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Protocol ID: CD34 Selection Disease: HSCT Who can participate?: 1. AML patients needing HSCT in first CR from MSD, with no post HSCT GvHD prophylaxis or 2. Primary or secondary graft failure after allogenic HSCT 3.Poor graft function after allogeneic HSCT 4. Graft source for allogeneic HSCT Lead Researcher: Rajinder P.S. Bajwa

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

Protocol ID: PIDTC 6903 Disease: CGD Who can participate?: CGD who have or will receive a transplant Lead Researcher: Hemalatha Geetharani Rangarajan

Haploidentical Hematopoietic Cell Transplant for Children with Hematologic Malignancies and Myelodysplasia

Protocol ID: HapLeuk17 Disease: HSCT Who can participate?: < 18 years of age. Patient lacks an HLA matched sibling donor. High resolution HLA and KIR typing. Lead Researcher: Mark A. Ranalli, MD

Impact of T and NK cell immune reconstitution on human Adenovirus (HAdV) infection in pediatric patients with allogeneic hematopoietic stem cell transplantation (HSCT)

Protocol ID: HAdV IR Disease: HSCT Who can participate?: Patients from 6 months to 18 years old who receive an allogenic HSCT at NCH. Lead Researcher: Eunkyung Song

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children with Sickle Cell Disease

Protocol ID: SUN Disease: Allogeneic HSCT Who Can Participate?: Ages 2 to 24.99 Lead Researcher: Hemalatha Geetharani Rangarajan, MD

NATIONWIDE CHILDREN’S HOSPITAL DIVISION OF HEMATOLOGY/ONCOLOGY/STEM CELL TRANSPLANT DATA COLLECTION CONSENT

Protocol ID: Stem Cell Data Collection Diseases: Allogeneic HSCT and Autologous HSCT Who Can Participate?: New Diagnosis Relapse/Refractory, ages 0 to 99 Lead Researcher: Jeffery J. Auletta, MD

The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

Protocol ID: ACCL1633 Disease: HCT Who can participate?: Patient must be ≥ 2 years of age and ≤ 25 years of age at time of enrollment. Patient must have a diagnosis that is managed with an alternative donor allogeneic hematopoietic cell transplant. Lead Researcher: Mark A. Ranalli

Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Protocol ID: NMDP/Data Collection Disease: HSCT Who can participate?: Any recipient of an unrelated or related donor or autologous HC transplant or any recipient of cellular therapy in a CIBMTR center is eligible to participate in the Research Database Lead Researcher: Jeffery J. Auletta, MD

Protocol for a Research Sample Repository for Allogeneic Hematopoietic Cell Transplantation and Marrow Toxic Injuries

Protocol ID: NMDP/Sample Repository Disease: HSCT Who can participate?: No specific age requirement Lead Researcher: Jeffery J. Auletta, MD